SEC Form 3 · accession 0001493152-18-009697
Provention Bio, Inc. · PRVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cameron Gray
Director
Period of report
Jul 3, 2018
Accepted (ET)
Jul 3, 2018 · 6:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001695357
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per share | holding | — | — | — | 1,080,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant (right to buy)F1 | $2.50 | holding | — | — | — | Apr 25, 2017 | Apr 25, 2024 | Series A Preferred Stock | 144,824 | — | D |
Explanation of responses
- F1Upon consummation of the initial public offering of Provention Bio, Inc. (the "Issuer"), each share of Series A Preferred Stock will automatically convert into one share of Common Stock, par value $0.0001 per share ("Common Stock") and the Warrant will automatically convert into a warrant to purchase Common Stock. Please see the Issuer's Registration Statement filed with the Securities Exchange Commission on Form S-1 (file no. 333-224801) for a complete description of the rights and preferences of the Series A Preferred Stock and Warrants.
Remarks
Exhibit List - Exhibit 24 - Power of Attorney